drug use by the parents increases the health risks for children

drug use by the parents increases the health risks for children -

Children whose parents or caregivers abuse alcohol or use , produce or distribute drugs face an increased risk of medical and behavioral problems. A new clinical report by experts from Beth Israel Medical Center (BIDMC) and the Children's Hospital Boston, pediatricians are in a unique position to assess the risk and intervene to protect children. The report, "the families affected by parental substance use," is available online today and scheduled for publication in the August print edition of Pediatrics , the journal of the American Association of Pediatrics.

"alcohol abuse and substance use are extremely common in this country, and the use of parents or caregivers substances can affect their ability to forge ever physical and emotional needs of basic priorities their children and provide a safe and stimulating environment, "says co-author Vincent C. Smith, MD, MPH, a neonatologist at BIDMC and Assistant Professor of Pediatrics at Harvard Medical School (HMS)." Because these children are risk of physical or emotional harm, pediatricians should know how to assess the risk of a child and support the family to get the help they need. "

it is estimated that one child in five in the United States grew up in a home where someone is abusing alcohol or a disorder of substance use, the authors write. Whether against the toxic effects of exposure to these substances or neglect of their basic needs by parents or guardians struggling with substance abuse problems, children of these households generally have developmental delays and education and, later, are at greater risk for mental health and behavior problems. They are also more likely than their peers to have consumer disorders substances themselves later in life.

In their report, Smith and co-author Celeste R. Wilson, MD, medical director of the child protection program at Boston Children's Hospital and assistant professor of pediatrics at HMS, examined the clinical signs of exposure of the fetus to alcohol, cannabis, stimulants and opioids. Pediatricians should be increasingly on the lookout for signs of neonatal abstinence syndrome (NAS), irritability, muscle stiffness, diarrhea - even seizures - that can result from prenatal exposure to opioids. Recent research indicates that 22,000 American babies were diagnosed in 2012 with NAS, the authors write, adding that more than a quarter of pregnant women were prescribed opioid analgesics during pregnancy, according to a separate study.

citing studies that say children whose parents use drugs and alcohol misuse are three times more likely to be physically, sexually or emotionally abused and four times more likely to be neglected than their peers, the authors urge all pediatricians to include questions on the substance of the use of carers within the evaluation of the family routine. Some warning signs of abuse and neglect include: injuries and easy bruising, especially in groups or in patterns that could indicate a contact with a hand, belt or other instrument; children who are withdrawn, fearful or Flinch to sudden movements; dental care or lack of vaccination; or ill-fitting, dirty or inappropriate clothing.

"Because pediatricians are the most likely to encounter families with young children who may be affected by the use of health care providers substances, they have the opportunity to help break multi-generational cycles of abuse, "the authors write." by being informed on the effects of drug use of parents on children, they can intervene if necessary. "

the authors provide examples of scripts to help clinicians begin a potentially bad talk at ease, noting that research suggests parents who screened positive for substance use are open to pediatricians by presenting them with tracking options such as community treatment programs. in the wake of these conversations, caregivers who do not choose treatment can still achieve some damage reduction by reducing or changing their substance, even if they do not refrain completely, Smith and Wilson noted.

"Pediatricians identifying substance abuse problems in a family are not supposed to solve, manage or treat these questions, but they can work with other professionals to provide families with access to resources" write Smith and Wilson. "Through screening, pediatricians have the opportunity to make a meaningful difference in the lives of the entire family affected by substance use."

CTBC Bank donated $ 0,000 to the Huntsman Cancer Foundation

CTBC Bank donated $ 0,000 to the Huntsman Cancer Foundation -

CTBC Bank (USA) and its parent company CTBC Financial Holdings donated $ 0,000 in as a global partner to the Huntsman cancer Foundation, which kicks off its new annual Championship research fundraising for cancer research.

The event, part of a golf campaign and gala will take place at Jack Nicklaus Course painted Promontory Valley in Park City, Utah, on August 12 and will benefit cancer research at the Huntsman cancer Institute in Salt Lake City, UT. Contributions, including CTBC total commitment of more than $ 1 million for fundraising.

"Cancer is really a global problem," said Susan Sheehan, Director General for Development at the Huntsman Cancer Foundation. "It takes a team of innovative researchers and optimistic, strong leadership and pioneering and dedicated partners to eradicate cancer. We are very grateful to CTBC generous support cancer and Huntsman children and families around the world. "

" CTBC Bank is proud to join the Huntsman Foundation Cancer to fight the disease by further strengthening his team and research facilities, "said Noor Menai, President and CEO of CTBC Bank (USA) and Chief CTBC North America." CTBC and our founders have a long tradition of supporting the communities we serve and the work of the foundation is essential for the future of families around the world. "

the CACT and the Huntsman gift support includes primary childhood and families' Cancer Research Center at Huntsman Cancer Institute . the center's research programs will increase knowledge about the genetics of cancer, risks and prevention, to advance the development of new drugs, providing state-of-the-art imaging of the tumor needs to address survivor, and create a biotechnology center.

In total, CTBC partners, Zions Bank, Layton Construction, Okland constuction, electrical Deseret, VLCM and Won-door, with dozens of other sponsors, will present more than $ 1 million in research with cancer aim to November of $ 2 million.

officials present CTBC August 12 ^e event to present the Huntsman Cancer Foundation a check for $ 0,000 include Thomas KS Chen, vice president of CTBC Bank Co., Peter Liu, Executive Vice President of CTBC, Noor Menai, and Kenneth Yu, vice president of CACT.

CTBC also supports many other important cultural and educational organizations, including the Center for Pacific Asian Family, Chrysalis and Operation Hope.

1-alpha antibody shows anti-interleukin new promise in the treatment of patients with advanced colorectal cancer

1-alpha antibody shows anti-interleukin new promise in the treatment of patients with advanced colorectal cancer -

A novel anti-interleukin-1 alpha antibody showed an impact significant about the symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to III data presented at the European Society for the 18th World Congress of medical oncology gastrointestinal cancer Barcelona, ​​Spain phase.

Xilonix is ​​the first monoclonal antibody immunotherapy to specifically target and neutralize interleukin-1 alpha (IL-1α), one of the most potent inflammatory substances produced by the cells of the body or a tumor.

"IL-1α in tumors promotes angiogenesis, helping to provide crucial blood supply to the tumor growth, and it can also send the metabolism of the body out of control, the causing it to burn muscle and lose weight, "said lead investigator Dr. Tamas Hickish. At the same time, the IL-1alpha effects on the brain can cause fatigue, anxiety and anorexia associated with advanced cancer.

The study included 309 patients with metastatic colorectal cancer whose disease has not responded to standard chemotherapy with oxaliplatin and irinotecan, which showed a high degree of symptoms , functional impairment, weight loss or elevated systemic inflammation.

In addition to trialing the new agent, the researchers also introduced new criteria for objective response based on controlling symptoms, which were developed in collaboration with the Scientific Working Group Board of European medicines Agency. These criteria have been applied in conjunction with dual-energy x-ray absorptiometry and EORTC-QLQC30 to assess disease control

Patients were randomized at a 2 :. Report 1 MABp1 with best supportive care or placebo and the same.

Treatment with MABp1 was associated with a relative increase of 76% clinically significant response rate. Patients who experienced a clinical response lived nearly three times longer than those who have not responded (11.5 months against 4.2 months).

The researchers also found that measures to improve the health status correlated with improvement in almost every other car measures reported by police and health laboratory, including with better control of the activity of white blood cells associated with the tumor and reduced systemic inflammation.

There was also a quarter of the less serious side effects in the treatment arm of the study compared with placebo.

"These data suggest Xilonix is ​​very well tolerated, and has the potential to meet the real and urgent need for more effective therapies, less toxic for patients with advanced colorectal cancer," said the Dr Hickish.

"This study also provides the first evidence that health can indeed be used to measure the effectiveness of anti-tumor therapy in advance, refractory colorectal cancer, and clinical responses based on health status can be a predictor of overall survival benefit. "

Argentine tango dance holds potential to reduce the risk of falls in cancer survivors with neuropathy

Argentine tango dance holds potential to reduce the risk of falls in cancer survivors with neuropathy -

Dance as a form of therapy - especially the Argentine tango - has the potential to significantly improve balance and reduce the risk of falls among cancer patients with peripheral neuropathy, according to a new study by a multidisciplinary research team at Ohio State University.

The pilot study was funded by Pelotonia, a popular cycling event in Columbus, Ohio, which has raised more than $ 106 million for research efforts on cancer in the Comprehensive Cancer Center at Ohio State University - Arthur G. James cancer Hospital and Richard J. Solove research Institute (OSUCCC of - James). Pelotonia stock and pre-med / major dance Mimi Lamantia worked with Lise Worthen-Chaudhari, a physical rehabilitation specialist who studies the movement to the Neurological Institute at Ohio State University Wexner Medical Center, to conduct the research study .

study addresses Prevalent Side effects of cancer treatment

Up to 70 percent of patients receiving chemotherapy will experience peripheral neuropathy as a side effect of cancer treatment . The condition can cause loss of sensation in the hands, fingers, feet and toes. One in 3 patients will still experience this issue six months after treatment.

The researchers say the long-term neuropathy in the feet and toes can be particularly problematic because it affects the balance and gait of a person. This puts them in a high risk of falling when they engage in daily living activities.

"This is a big problem because many more people survive cancer. Dealing with issues that impact on the quality of a person's life after cancer is extremely important," says Worthen -Chaudhari, a faculty member in the Department of the USO of physical medicine and rehabilitation. "As a dancer, I studied the art of movement and as a biomechanics and rehabilitation science, I studied mathematics and the science of motion. We thought it would be a powerful combination to bring everyone together to try help cancer survivors. "

To evaluate the effect of the practice of Argentine tango on the biomechanical risk predictors of falls in cancer survivors, Worthen-Chaudhari and Lamantia designed a dance intervention course that involved 20 sessions adapted Argentine Tango. Patients participated in a one-hour session twice a week for 10 weeks.

standing postural sway

Researchers measured patients (eyes closed) with a platform for computer aided strength early in the series of intervention of dance and at the end of the 10 weeks of instruction. They were also asked patients to report satisfaction with the intervention.

"So many patients tell us that it's hard to stay attached to physical therapy because it is difficult and feels like work. We show that the tango has measurable effects on balance -. but our patients really say enjoying the dance therapy as it is a fun and social way to do the work and our initial data shows it has a positive impact to restore balance, "says Lamantia who taught Argentine Tango in a class of about 30 cancer survivors in this study.

initial data of the first three patients who participated in the Argentine tango study will be presented on November 3 2016, at the annual meeting 2016 of the American Congress of rehabilitation medicine in Chicago, Illinois.

"We show that after only five weeks of Argentine tango, medial and lateral roll of the trailer fell by 56 percent indicating that this is a promising intervention to balance cancer survivors experiencing post processing deficiency balance "says Lamantia.

This work provides the first known evidence about whether cancer survivors find an intervention based on dance, Argentine tango, satisfactory and feasible for improving balance.

"as an educator of dance I have personally witnessed the immeasurable joy, confidence and a better quality of motion in each Argentine tango dancer in the 10 weeks," adds Lamantia.

The researchers attributed $ 3.3 million NIH grant to study the role of genetics in protecting against fragility

The researchers attributed $ 3.3 million NIH grant to study the role of genetics in protecting against fragility -

The brittleness is a common condition associated with old age, characterized by weight loss, weakness, decreased activity level and reduced mobility, thereby increasing the risk of injury and death. Yet all seniors become brittle; some remain vigorous and robust well into old age. The question remains: why

the Albert Einstein College of Medicine Researchers at Yeshiva University have received a grant of $ 3.3 million from the National Institutes of Health (NIH) to study the role of genetics in protecting against fragility. The study will be conducted by Nir Barzilai, MD, director of the Institute for Research on Aging and Leon Rennert Chair Ingeborg and Ira in aging research at Einstein and attending physician, medicine at Montefiore Medical Center, and Joe Verghese, MBBS, D Murray. Gross Memorial Faculty Scholar in Gerontology at Einstein, chief of geriatrics at Einstein and Montefiore Einstein Center and director of the Montefiore for brain aging.

"people who are frail are more vulnerable to serious complications due to falls or surgery and more susceptible to infection," said Dr. Verghese. "Understanding why some elderly suffer loss balance or strength, and do not suffer from abnormal gait can help us to prevent and treat such a physical decline. "

The new project draws on the resources LonGenity research Einstein study, which is based on the longevity genes Project, an ongoing study of 15 with more than 500 Ashkenazi Jews over the age 95. LonGenity compares the genetics of centenarians and their children with those with the usual survival. Over the past 10 years, the team of Dr. Barzilai has identified several biomarkers that can explain their extreme longevity.

"We found that our centenarian participants have a significant genetic advantage over the general population. Their rare genetic variants helped to live longer, healthier and prevent or significantly delay related diseases age, such as Alzheimer's disease and type 2 diabetes, "said Dr. Barzilai,." We want to know whether a family history of these "longevity genes" reduces the risk of fragility. "

the researchers will build a pilot study funded by the American Federation for aging research that links the exceptional longevity to improve physical function and reduced risk of fragility. the Einstein team plans to continue these early efforts to identify genetic variants that prevent frailty in the bay, explore the biological pathways that can lead to fragility and develop drugs that mimic the effect of the prevention of fragility genes.

Five -Year grant, "Role of exceptional longevity genotypes in protecting against fragility in aging" (R01AG044829), was awarded by the National Institute on Aging, part of the NIH.

BU researcher receives grant to better understand breast cancer among African-American women

BU researcher receives grant to better understand breast cancer among African-American women -

Why are African American women die at a higher rate and the experience more aggressive breast tumors than white women? Researchers at Slone Epidemiology Center at Boston University (SEC) received funding from the National Cancer Institute (NCI) to explore this issue. The new grant is based on the premise that to have a better understanding of breast cancer biology in African-American women will lead to better prevention and treatment.

"Identification of genetic variants linked to breast cancer in African-American women to deepen our knowledge of the disease and ultimately may lead us to better treatments and prevention opportunities," said Julie R. Palmer, ScD, senior epidemiologist at SEC and BU professor of epidemiology at the school of public health from Boston University, who is leading the study at BU.

breast cancer is not one disease, but a combination of subtypes distinct diseases with different risk factors and clinical outcomes. However, the reasons for differences in breast cancer biology and disparities in incidence and mortality rates between white women and African-Americans are not well understood, and existing studies were not large enough to provide sufficient statistical power to elucidate the genetic factors associated with how breast cancers develop. The size and power of this new study could help resolve the current lack of scientific understanding.

"Health disparities are a major concern problem for the NCI and we are focused on as evidenced by this grant," said the acting director of NCI, Douglas Lowy, MD

This study will seek to identify new genes and genetic pathways that influence breast cancer among African-American women.

This multicenter study will pool data, biological samples, and expertise of 18 previous studies of breast cancer in women of African descent. Investigators determine whether genetic variants may be associated with increased risk. Specifically, they will examine:

• The association between genetic variants and risk of breast cancer with estrogen receptor negative and estrogen-positive breast cancers receiver
• How genetic variants affect major breast cancer biological pathways and whether the effects may differ between African American women and white women

The results provide better treatment options for children with leukemia

The results provide better treatment options for children with leukemia -

A research team led by Nanyang Technological University (NTU) scientists have made a key finding which should open improving treatment options for children with leukemia.

They found that two in three cases of acute lymphoblastic leukemia, a type of cancer of white blood cells, can be caused by mutations in one of two key genes found in children. These genes, however, are more common in people with Down syndrome.

This means that scientists can design better treatment protocols, depending on the mutated gene is carried by the patient. These treatments may include lower doses of anticancer drugs thus leading to less side effects.

Acute lymphoblastic leukemia is the most common cancer in children, with 50 to 100 children diagnosed annually in Singapore. This gene discovery is good news for those with Down syndrome and 20 percent of children who do not respond well to standard therapy.

Children with Down syndrome have 20 to 50 times greater risk of developing blood cancer. They are also likely to suffer a relapse and have a higher risk of dying from side effects of the therapy.

The discovery, made by an international team led by Professor Dean Nizetic Lee Kong Chian School of Medicine NTU, was published in the prestigious scientific journal Nature Communications last week.

expert team of Prof. Nizetic in aging and Down syndrome have collaborated with researchers at Queen Mary University in London and the Universities of Geneva and Padua on this study.

"by analyzing the DNA sequence of samples at different stages of the disease patients, we identified mutations in two genes that transform normal blood cells into cancer cells," said Professor Nizetic, lead author of the study.

research team found that two genes (RAS and JAK) does mutate together, making them ideal biomarkers.

"this could benefit all children affected by the disease as clinicians would be able to offer appropriate treatment, more specific and less toxic, reducing side effects and even a reduction in deaths related side-effects' added Professor Nizetic.

team of Prof. Nizetic at LKCMedicine focuses on Down syndrome for better understanding of the condition, which has many complex mysteries. In people with Down syndrome, their cells show signs of accelerated aging and damage of accumulated DNA. Paradoxically, they appear to be protected against the most common cancers of solid tissues in adulthood.

"Some people with Down syndrome may be protected against age-related diseases such as dementia, atherosclerosis and type II diabetes, despite the increased risk factors," said Professor Nizetic.

"Examine those cells with Down syndrome could not only help to lead longer and healthier lives, but also provide important clues in understanding general mechanisms of aging, Alzheimer ' Alzheimer's, cancer, atherosclerosis, diabetes, and a number of other common conditions, which so far has not been sufficiently explored. "

Moving forward, the 'NTU research team will conduct more studies on the results of two key genes. This is to see how well they could affect normal children and children with Down syndrome, who suffer from this form of leukemia.

Down Syndrome Association (Singapore) welcomed the discovery

Dr Balbir Singh, advisor and founding president of Down Syndrome Association (Singapore), hope these findings will lead to "better treatment less toxic to all children affected by this disease, "and welcomed the new interest in research in Down syndrome

" associations and organizations of parents and carers for people with Down syndrome are very interested in participating in research that could improve the prospects for improving their health, quality of life and inclusion in society, "said Dr. Singh.

"It makes people with Down syndrome twice as proud, and feel important and included if their study may help to better understand and combat diseases such as Alzheimer's disease, cerebrovascular accident, heart attack and cancer, for all people. The Down Syndrome Association (Singapore) welcomes more research in this direction. "

The anti-EphA3 antibody has anti-tumor effects against solid cancers

The anti-EphA3 antibody has anti-tumor effects against solid cancers -

An international team of scientists has shown that antibodies against the EphA3 protein found in the microenvironment of the solid cancers, has anti-tumor effects.

As EphA3 is present in normal organs during embryonic development, but is expressed in blood cancers and solid tumors, the antibody-based approach can be a treatment for solid tumors suitable candidate .

researchers from Monash University and the Ludwig Cancer Research, Australia, and KaloBios Pharmaceuticals, the United States, had their results published in the journal Cancer Research .

team, jointly led by the late Professor Martin Lackmann, School of Biomedical Sciences at Monash; and Professor Andrew Scott of Ludwig Cancer Research, found that although tumor cells lack this molecule they can prosper by attracting and leveraging support cells containing EphA3 in the tumor microenvironment.

First author Dr. Mary Vail, Monash Department of Biochemistry and Molecular Biology said "the tumor cells send signals to the surrounding area and say," We need a blood supply and a basis on which to spread. "

" We have shown that EphA3 expressing stem stromal cells, which are produced by the bone marrow, as cells that support and create blood vessels in tumors, " said Dr. Vail.

the team of Professor Andrew Scott Ludwig introduced human prostate cancer cells in a mouse model to mimic disease progression in humans. EphA3 was found in the stromal cells and the blood vessels surrounding the tumor.

They also observed that treatment with an antibody against EphA3 (chIIIA4) significantly slowed tumor growth. The antibodies damaged the blood vessels of the tumor and disrupted the microenvironment stromal and cancer cells died because their "life support" was compromised

"In addition, we screened various tumors from patient biopsies -. sarcomas, melanomas and prostate, colon, breast, brain and lung cancer - and confirmed the expression of EphA3 on stromal and newly forming blood vessels cells, " said Professor Scott

. " Our research results indicate that the tumor microenvironment is important, and monoclonal antibodies against EphA3 are a way to target and kill a variety of solid tumors and blood cancers. "

Currently, KaloBios Pharmaceuticals is testing the anti-EphA3 KB004 antibodies in a phase multi-center I / II clinical trial in Melbourne and the US in patients with EphA3 expressing malignancies blood :. AML, MDS and myelofibrosis

Dr Vail, who collaborated with his former mentor on the project for 10 years, said the research represented the work of Martin's life Lackmann.

"Martin has been dedicated to helping people, and felt that KB004 is a promising therapeutic approach. It rightly states that it would be well tolerated in patients with cancer, and through this collaborative project, his pioneering research has progressed to clinical trials and potential new treatments for cancer patients " said Dr. Vail.

fragments of tumor DNA in the blood may help identify the risk of recurrence of colorectal cancer

fragments of tumor DNA in the blood may help identify the risk of recurrence of colorectal cancer -

Ludwig researchers working in collaboration with colleagues in Australia and the United States States have shown that tumor DNA fragments circulating in the blood can be used to assess the risk of colorectal cancer recurrence and the efficacy of chemotherapy following surgery. The discovery, published today in the current issue of Science Translational Medicine , is an important step towards developing a non-invasive and effective test for the detection, monitoring and treatment Cancer.

"Previous studies, including our group, have shown that this technique is sensitive enough to detect tumor DNA fragments in patients with advanced cancer," Bert Vogelstein, co-director the Ludwig Center at Johns Hopkins and one of the leaders of the study. "But this new study brings us a big step closer to the real purpose, because it suggests that it can detect residual disease in patients at an early stage, long before conventional clinical or radiological criteria can."

The decision of whether a stage II colon cancer patients should be treated with adjuvant, or post-surgery, chemotherapy remains one of the most difficult areas in colorectal oncology. These assessments are being made by combining a number of clinical and pathological features - such as the appearance of the tumor under the microscope, including how far it has spread through the wall of the intestine - or looking for presence of specific genetic markers of cancer that have prognostic significance.

However, current methods are inaccurate, and therefore doctors tend to err on the side of caution. Currently, up to 40 percent of stage II patients undergo the rigors and risks of adjuvant chemotherapy, although only a small fraction of them are for a relapse of cancer.

"The routine procedure is to give six months of chemotherapy, but we have no way of knowing whether the treatment is effective," said Jeanne Tie, an investigator with the Ludwig Institute and Walter Eliza hall of Medical Research (WEHI) in Victoria, Australia, and lead author of the study.

cancer cells often shed their DNA in the blood when they die, and recent technological advances have capture and profile of these relatively rare fragments of DNA. mutations in the tumor DNA circulating (ctDNA) can serve as highly specific biomarkers of cancer.

"We must be able to choose a DNA single tumor among ten thousand fragments of DNA normal, "said Tie." This is the sensitivity that we needed to come down to, and it has not been possible until now. "

for the current study, Tie and colleagues collected samples of tumors from 230 patients with stage II colorectal cancer. They analyzed the DNA of tumor samples and customized tests designed to target particular genetic mutations of each patient.

The tests were applied to blood samples taken from patients four to 10 weeks after surgery to remove tumors. Twenty of the 230 patients who tested positive for ctDNA, and of that group, 80 percent experienced a cancer recurrence in about two years. Of the 164 patients whose blood tested negative for ctDNA, only 10 percent relapse.

"A positive ctDNA test is an indicator that cancer cells from the original tumor are hiding somewhere in the body," said Peter Gibbs, a researcher at Ludwig WEHI who co-directed the study with Tie and Vogelstein.

the team also investigated whether ctDNA could be used to assess the impact of chemotherapy. Six tested positive patients ctDNA after surgery also underwent adjuvant chemotherapy. Scientists have continued to collect blood samples from these patients and found that in two patients, ctDNA readings changed from positive after surgery to negative after chemotherapy.

"In an oncologist, who is probably the most exciting one screening test ctDNA appearance - it can be used not only to determine the risk of recurrence, but also as a real-time marker chemotherapy benefit, "said Gibbs

in the present study, the tests were ctDNA CUSTOM-. tailored to the unique cancerous mutations in each patient, but scientists are also developing a test that ctDNA frequently covers occurring mutations of colorectal cancer.

"When such a generic test is developed, it could still take more than 0 percent of colorectal cancers, and it would eliminate the need to recover and test samples of individual tumors, saving time, effort and money, "said Gibbs.

I-SPY2 research initiative employs new exciting model to test drugs against breast cancer

I-SPY2 research initiative employs new exciting model to test drugs against breast cancer -

In a new paradigm of research on breast cancer, doctors promising new drug for more rapid monitoring study, while immediately giving up drugs and combinations of drugs that do not work.

Loyola medical oncologist Kathy Albain S., MD, FACP, FASCO is a co-author of two of these studies, published in the July 7, 2016 New England Journal of Medicine . Studies have shown that patients with specific subtypes of breast cancer, drug neratinib and veliparib the combination of drug plus carboplatin were more effective in eradicating tumors prior to surgery as the standard chemotherapy alone.

The studies are part of a nationwide research initiative called I-SPY2. Dr. Albain is the principal investigator at Loyola, one of only two academic medical centers in Illinois participating in I-SPY2.

"I-SPY2 employs an exciting new model for testing drugs," said Dr. Albain. "The tests are not run this way before in breast cancer Now we can determine much more earlier that the drugs are active, while minimizing the exposure of patients to drugs that do not work - .. as the trial progresses day by day "

Dr. Albain, professor, department of medicine, division of hematology / oncology, Loyola University Chicago Stritch of School of medicine, is also a member of the National I-SPY2 New agents and wire Committee "chaperone" of another study I-SPY2 for drug trebananib experimental.

I-SPY2 researchers use profiles of breast cancer cell gene biomarkers to determine which experimental study drug is most suited to the profile of the tumor of a given patient.

"patient treatment is targeted, real-time, the biology of the tumor," said Dr. Albain. "I-SPY2 allows us to bring exciting new agents in the curative setting faster than the standard method of the first test extensively in large multi-year trials."

The I-SPY2 studies were conducted in patients before they underwent surgery. These studies allow drugs to be tested in small trials, with faster results.

The researchers examined whether experimental treatments have resulted in the complete eradication of tumors before surgery. eradication of the tumor does not necessarily mean a patient is cured and must still undergo surgery. But women who experience eradicating tumor before surgery were less likely to relapse or die of breast cancer.

In one SPY2 I-studies published recently, the researchers examined the drug neratinib, who was very active in patients with a type of breast cancer known as HER2-positive name, negative hormone receptors. Fifty-six percent of patients who were treated with neratinib and the eradication of standard treatment known tumor before surgery, compared to 33 percent of patients who received standard therapy alone

. The second trial involved patients who had a type of breast cancer called triple negative cancer. Fifty-one percent of women who received veliparib and carboplatin with standard therapy experienced eradication of the tumor before surgery, compared to 26 percent of women who received standard treatment alone.

Based on these results, experimental drugs are being accelerated large-scale phase 3

in an article accompanying perspective, researchers at the Dana-Institut Farber Cancer and the Harvard school of public health, who are not involved in the trial, wrote that I- SPY2 is "an important addition to the inventory of test designs." the authors perspective, David Harrington, PhD, and Giovanni Parmigiani, PhD, concluded: "We applaud the use of I-SPY2 described here and urge continued innovation in trial design, especially in the two phases 1 and later 3 previous settings. "